ISTH 2022 Congress
Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies » Platelet Antagonists and Novel Therapeutics
Theme Navigation
- ISTH 2022 Congress
- Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies
- Platelet Antagonists and Novel Therapeutics
- Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies
-
Abstract Number: OC 73.4
Characterization of a novel anti-GPVI antibody in a humanized GP6 (hGP6KI) mouse model
-
Abstract Number: VPB0350
Curcumin potentiates an inhibitory effect of cangrelor on platelets
-
Abstract Number: PB0347
Efgartigimod: A Novel FcRn Antagonist in the Treatment of Autoimmune Diseases
-
Abstract Number: PB0346
Inhibition of PI3KC2alpha selectively reduces platelet recruitment after vascular injury while preserving thrombus architecture
-
Abstract Number: VPB0349
ML355 modulates platelet activation and prevents ABT-737 induced apoptosis in platelets
-
Abstract Number: PB0343
N-Acetyl Cysteine Prevents Occlusive Arterial Thrombosis in a Dose-Dependent Manner
-
Abstract Number: PB0348
Small-molecule cyclophilin inhibitors as a potential therapeutic application to limit thrombosis
-
Abstract Number: PB0345
Targeting platelet Glycoprotein VI with Glenzocimab: a novel mechanism of inhibition
-
Abstract Number: PB0344
Use of romiplostim in paediatric patients with immune thrombocytopenic purpura (ITP)